[ad_1]
FILE | John Cairns | AFP
visits
Argentina awarded this Wednesday the emergency authorization for the covid-19 vaccine developed by the AstraZeneca laboratory and the University of Oxfordhours after getting approval in the UK, the National Medicines Administration reported.
The product, for which Argentina has a manufacturing agreement, was registered in the “registry of vaccines of health interest in emergencies” for a period of one year, said that body in its resolution.
The approval is given in full vaccination process started on Tuesday with the Russian vaccine Sputnik V, of which Argentina received a first batch of 300,000 doses last Thursday.
“The product presents an acceptable benefit-risk balance, allowing to sustain the granting of the inscription”, indicated the ANMAT.
The agency specified that “The Risk Management Plan must be complied with (PGR) established to closely monitor the safety and efficacy of the drug and submit progress reports and the corresponding modifications to the National Institute of Medications ”.
Argentina and Mexico have an agreement to produce the vaccine that Oxford developed together with AstraZeneca and distribute it in Latin America.
This is the third coronavirus vaccine approved in Argentina, after those of Pfizer / BioNTech and Sputnik V of the Russian laboratory Gamaleya.
Argentina is still in negotiations to acquire Pzifer / BioNTech.
This South American country of 44 million inhabitants has registered since March more than 1.6 million infections and exceeds 43 thousand deaths.
In total, the government of Alberto Fernández plans to acquire about 51 million doses of different vaccines.
Argentina participated in volunteer trials of phase 3 of the Pfizer / BioNTech vaccine, as well as that of the Chinese group Sinopharm.
[ad_2]
